Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Synthekine
Shionogi Inc.
GI Innovation, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Genmab
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Servier
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Seagen Inc.
Xencor, Inc.
Biocity Biopharmaceutics Co., Ltd.
PMV Pharmaceuticals, Inc
Mayo Clinic
D3 Bio (Wuxi) Co., Ltd
Dartmouth-Hitchcock Medical Center
Aminex Therapeutics, Inc.
Merck Sharp & Dohme LLC
NeoImmuneTech
Revolution Medicines, Inc.
Verastem, Inc.
Immunocore Ltd
H. Lee Moffitt Cancer Center and Research Institute
Pyxis Oncology, Inc
Genmab
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Eikon Therapeutics
Astellas Pharma Inc
AbbVie
BioInvent International AB
Qurient Co., Ltd.
Intima Bioscience, Inc.
Dana-Farber Cancer Institute
Duke University
Hoffmann-La Roche
Providence Health & Services
BioInvent International AB
Merck Sharp & Dohme LLC
Essen Biotech
Merck Sharp & Dohme LLC